nodes	percent_of_prediction	percent_of_DWPC	metapath
Isradipine—CACNA1S—seminal vesicle—testicular cancer	0.0212	0.166	CbGeAlD
Isradipine—CACNA1H—seminal vesicle—testicular cancer	0.0135	0.105	CbGeAlD
Isradipine—CACNA1H—gonad—testicular cancer	0.00974	0.0762	CbGeAlD
Isradipine—CACNA2D2—testis—testicular cancer	0.00865	0.0677	CbGeAlD
Isradipine—CACNA1H—female gonad—testicular cancer	0.00791	0.0619	CbGeAlD
Isradipine—CACNA1H—testis—testicular cancer	0.00702	0.0549	CbGeAlD
Isradipine—CACNA2D1—female gonad—testicular cancer	0.00702	0.0549	CbGeAlD
Isradipine—CACNB2—testis—testicular cancer	0.00663	0.0519	CbGeAlD
Isradipine—CACNA2D2—lymph node—testicular cancer	0.00627	0.0491	CbGeAlD
Isradipine—CACNA2D1—testis—testicular cancer	0.00622	0.0487	CbGeAlD
Isradipine—CACNA1D—testis—testicular cancer	0.00579	0.0453	CbGeAlD
Isradipine—CACNA1C—testis—testicular cancer	0.00535	0.0419	CbGeAlD
Isradipine—CACNA1H—lymph node—testicular cancer	0.00509	0.0398	CbGeAlD
Isradipine—CACNB2—lymph node—testicular cancer	0.0048	0.0376	CbGeAlD
Isradipine—CACNA2D1—lymph node—testicular cancer	0.00451	0.0353	CbGeAlD
Isradipine—CACNA1D—lymph node—testicular cancer	0.0042	0.0329	CbGeAlD
Isradipine—CACNA1C—lymph node—testicular cancer	0.00388	0.0303	CbGeAlD
Isradipine—Anaphylactic shock—Etoposide—testicular cancer	0.00156	0.00179	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00155	0.00178	CcSEcCtD
Isradipine—Asthenia—Dactinomycin—testicular cancer	0.00155	0.00177	CcSEcCtD
Isradipine—Paraesthesia—Cisplatin—testicular cancer	0.00153	0.00175	CcSEcCtD
Isradipine—Thrombocytopenia—Etoposide—testicular cancer	0.00153	0.00175	CcSEcCtD
Isradipine—Tachycardia—Etoposide—testicular cancer	0.00152	0.00175	CcSEcCtD
Isradipine—Liver function test abnormal—Doxorubicin—testicular cancer	0.00152	0.00174	CcSEcCtD
Isradipine—Dyspnoea—Cisplatin—testicular cancer	0.00152	0.00174	CcSEcCtD
Isradipine—Skin disorder—Etoposide—testicular cancer	0.00152	0.00174	CcSEcCtD
Isradipine—Erectile dysfunction—Methotrexate—testicular cancer	0.00151	0.00174	CcSEcCtD
Isradipine—Hyperhidrosis—Etoposide—testicular cancer	0.00151	0.00173	CcSEcCtD
Isradipine—Photosensitivity reaction—Methotrexate—testicular cancer	0.0015	0.00172	CcSEcCtD
Isradipine—Angina pectoris—Epirubicin—testicular cancer	0.0015	0.00172	CcSEcCtD
Isradipine—Breast disorder—Doxorubicin—testicular cancer	0.00149	0.00171	CcSEcCtD
Isradipine—Decreased appetite—Cisplatin—testicular cancer	0.00148	0.0017	CcSEcCtD
Isradipine—Diarrhoea—Dactinomycin—testicular cancer	0.00148	0.00169	CcSEcCtD
Isradipine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00147	0.00169	CcSEcCtD
Isradipine—Vomiting—Bleomycin—testicular cancer	0.00147	0.00169	CcSEcCtD
Isradipine—Drowsiness—Methotrexate—testicular cancer	0.00147	0.00168	CcSEcCtD
Isradipine—Depression—Methotrexate—testicular cancer	0.00146	0.00168	CcSEcCtD
Isradipine—Hypotension—Etoposide—testicular cancer	0.00146	0.00167	CcSEcCtD
Isradipine—Rash—Bleomycin—testicular cancer	0.00146	0.00167	CcSEcCtD
Isradipine—Dermatitis—Bleomycin—testicular cancer	0.00146	0.00167	CcSEcCtD
Isradipine—Pollakiuria—Epirubicin—testicular cancer	0.00142	0.00163	CcSEcCtD
Isradipine—Asthenia—Ifosfamide—testicular cancer	0.00142	0.00163	CcSEcCtD
Isradipine—Photosensitivity reaction—Epirubicin—testicular cancer	0.0014	0.00161	CcSEcCtD
Isradipine—Feeling abnormal—Cisplatin—testicular cancer	0.0014	0.00161	CcSEcCtD
Isradipine—Paraesthesia—Etoposide—testicular cancer	0.0014	0.00161	CcSEcCtD
Isradipine—Weight increased—Epirubicin—testicular cancer	0.0014	0.0016	CcSEcCtD
Isradipine—Pruritus—Ifosfamide—testicular cancer	0.0014	0.0016	CcSEcCtD
Isradipine—Dyspnoea—Etoposide—testicular cancer	0.00139	0.00159	CcSEcCtD
Isradipine—Somnolence—Etoposide—testicular cancer	0.00139	0.00159	CcSEcCtD
Isradipine—Angina pectoris—Doxorubicin—testicular cancer	0.00139	0.00159	CcSEcCtD
Isradipine—Hepatobiliary disease—Methotrexate—testicular cancer	0.00139	0.00159	CcSEcCtD
Isradipine—Nausea—Bleomycin—testicular cancer	0.00137	0.00157	CcSEcCtD
Isradipine—Drowsiness—Epirubicin—testicular cancer	0.00137	0.00157	CcSEcCtD
Isradipine—Vomiting—Dactinomycin—testicular cancer	0.00137	0.00157	CcSEcCtD
Isradipine—Rash—Dactinomycin—testicular cancer	0.00136	0.00156	CcSEcCtD
Isradipine—Decreased appetite—Etoposide—testicular cancer	0.00136	0.00156	CcSEcCtD
Isradipine—Diarrhoea—Ifosfamide—testicular cancer	0.00135	0.00155	CcSEcCtD
Isradipine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00135	0.00154	CcSEcCtD
Isradipine—Fatigue—Etoposide—testicular cancer	0.00135	0.00154	CcSEcCtD
Isradipine—Constipation—Etoposide—testicular cancer	0.00133	0.00153	CcSEcCtD
Isradipine—Hepatitis—Methotrexate—testicular cancer	0.00132	0.00151	CcSEcCtD
Isradipine—Pollakiuria—Doxorubicin—testicular cancer	0.00131	0.00151	CcSEcCtD
Isradipine—Dizziness—Ifosfamide—testicular cancer	0.00131	0.0015	CcSEcCtD
Isradipine—Urinary tract disorder—Methotrexate—testicular cancer	0.0013	0.00149	CcSEcCtD
Isradipine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.0013	0.00149	CcSEcCtD
Isradipine—Hepatobiliary disease—Epirubicin—testicular cancer	0.0013	0.00149	CcSEcCtD
Isradipine—Weight increased—Doxorubicin—testicular cancer	0.0013	0.00148	CcSEcCtD
Isradipine—Urethral disorder—Methotrexate—testicular cancer	0.00129	0.00148	CcSEcCtD
Isradipine—Feeling abnormal—Etoposide—testicular cancer	0.00129	0.00147	CcSEcCtD
Isradipine—Nausea—Dactinomycin—testicular cancer	0.00128	0.00147	CcSEcCtD
Isradipine—Drowsiness—Doxorubicin—testicular cancer	0.00127	0.00145	CcSEcCtD
Isradipine—Visual impairment—Methotrexate—testicular cancer	0.00127	0.00145	CcSEcCtD
Isradipine—Vomiting—Ifosfamide—testicular cancer	0.00126	0.00144	CcSEcCtD
Isradipine—Bradycardia—Epirubicin—testicular cancer	0.00125	0.00144	CcSEcCtD
Isradipine—Rash—Ifosfamide—testicular cancer	0.00125	0.00143	CcSEcCtD
Isradipine—Dermatitis—Ifosfamide—testicular cancer	0.00124	0.00143	CcSEcCtD
Isradipine—Urticaria—Etoposide—testicular cancer	0.00124	0.00142	CcSEcCtD
Isradipine—Hepatitis—Epirubicin—testicular cancer	0.00123	0.00141	CcSEcCtD
Isradipine—Eye disorder—Methotrexate—testicular cancer	0.00123	0.00141	CcSEcCtD
Isradipine—Hypoaesthesia—Epirubicin—testicular cancer	0.00122	0.0014	CcSEcCtD
Isradipine—Asthenia—Cisplatin—testicular cancer	0.00122	0.0014	CcSEcCtD
Isradipine—Cardiac disorder—Methotrexate—testicular cancer	0.00122	0.0014	CcSEcCtD
Isradipine—Urinary tract disorder—Epirubicin—testicular cancer	0.00122	0.00139	CcSEcCtD
Isradipine—Oedema peripheral—Epirubicin—testicular cancer	0.00121	0.00139	CcSEcCtD
Isradipine—Connective tissue disorder—Epirubicin—testicular cancer	0.00121	0.00139	CcSEcCtD
Isradipine—Urethral disorder—Epirubicin—testicular cancer	0.00121	0.00138	CcSEcCtD
Isradipine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.0012	0.00138	CcSEcCtD
Isradipine—Angiopathy—Methotrexate—testicular cancer	0.00119	0.00137	CcSEcCtD
Isradipine—Immune system disorder—Methotrexate—testicular cancer	0.00119	0.00136	CcSEcCtD
Isradipine—Visual impairment—Epirubicin—testicular cancer	0.00119	0.00136	CcSEcCtD
Isradipine—Mediastinal disorder—Methotrexate—testicular cancer	0.00119	0.00136	CcSEcCtD
Isradipine—Nausea—Ifosfamide—testicular cancer	0.00117	0.00135	CcSEcCtD
Isradipine—Diarrhoea—Cisplatin—testicular cancer	0.00117	0.00134	CcSEcCtD
Isradipine—Bradycardia—Doxorubicin—testicular cancer	0.00116	0.00133	CcSEcCtD
Isradipine—Mental disorder—Methotrexate—testicular cancer	0.00115	0.00132	CcSEcCtD
Isradipine—Eye disorder—Epirubicin—testicular cancer	0.00115	0.00132	CcSEcCtD
Isradipine—Malnutrition—Methotrexate—testicular cancer	0.00115	0.00131	CcSEcCtD
Isradipine—Cardiac disorder—Epirubicin—testicular cancer	0.00114	0.00131	CcSEcCtD
Isradipine—Flushing—Epirubicin—testicular cancer	0.00114	0.00131	CcSEcCtD
Isradipine—Hepatitis—Doxorubicin—testicular cancer	0.00114	0.00131	CcSEcCtD
Isradipine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00113	0.0013	CcSEcCtD
Isradipine—Urinary tract disorder—Doxorubicin—testicular cancer	0.00112	0.00129	CcSEcCtD
Isradipine—Oedema peripheral—Doxorubicin—testicular cancer	0.00112	0.00129	CcSEcCtD
Isradipine—Asthenia—Etoposide—testicular cancer	0.00112	0.00128	CcSEcCtD
Isradipine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00112	0.00128	CcSEcCtD
Isradipine—Angiopathy—Epirubicin—testicular cancer	0.00112	0.00128	CcSEcCtD
Isradipine—Urethral disorder—Doxorubicin—testicular cancer	0.00112	0.00128	CcSEcCtD
Isradipine—Immune system disorder—Epirubicin—testicular cancer	0.00111	0.00127	CcSEcCtD
Isradipine—Mediastinal disorder—Epirubicin—testicular cancer	0.00111	0.00127	CcSEcCtD
Isradipine—Back pain—Methotrexate—testicular cancer	0.00111	0.00127	CcSEcCtD
Isradipine—Pruritus—Etoposide—testicular cancer	0.0011	0.00127	CcSEcCtD
Isradipine—Visual impairment—Doxorubicin—testicular cancer	0.0011	0.00126	CcSEcCtD
Isradipine—Vomiting—Cisplatin—testicular cancer	0.00108	0.00124	CcSEcCtD
Isradipine—Vision blurred—Methotrexate—testicular cancer	0.00108	0.00124	CcSEcCtD
Isradipine—Mental disorder—Epirubicin—testicular cancer	0.00108	0.00124	CcSEcCtD
Isradipine—Rash—Cisplatin—testicular cancer	0.00107	0.00123	CcSEcCtD
Isradipine—Dermatitis—Cisplatin—testicular cancer	0.00107	0.00123	CcSEcCtD
Isradipine—Malnutrition—Epirubicin—testicular cancer	0.00107	0.00123	CcSEcCtD
Isradipine—Diarrhoea—Etoposide—testicular cancer	0.00107	0.00122	CcSEcCtD
Isradipine—Eye disorder—Doxorubicin—testicular cancer	0.00106	0.00122	CcSEcCtD
Isradipine—Ill-defined disorder—Methotrexate—testicular cancer	0.00106	0.00122	CcSEcCtD
Isradipine—Anaemia—Methotrexate—testicular cancer	0.00106	0.00121	CcSEcCtD
Isradipine—Cardiac disorder—Doxorubicin—testicular cancer	0.00106	0.00121	CcSEcCtD
Isradipine—Flushing—Doxorubicin—testicular cancer	0.00106	0.00121	CcSEcCtD
Isradipine—Tension—Epirubicin—testicular cancer	0.00105	0.00121	CcSEcCtD
Isradipine—Nervousness—Epirubicin—testicular cancer	0.00104	0.00119	CcSEcCtD
Isradipine—Back pain—Epirubicin—testicular cancer	0.00104	0.00119	CcSEcCtD
Isradipine—Angiopathy—Doxorubicin—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Malaise—Methotrexate—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Dizziness—Etoposide—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Muscle spasms—Epirubicin—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Immune system disorder—Doxorubicin—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Leukopenia—Methotrexate—testicular cancer	0.00103	0.00118	CcSEcCtD
Isradipine—Nausea—Cisplatin—testicular cancer	0.00101	0.00116	CcSEcCtD
Isradipine—Vision blurred—Epirubicin—testicular cancer	0.00101	0.00116	CcSEcCtD
Isradipine—Cough—Methotrexate—testicular cancer	0.000999	0.00115	CcSEcCtD
Isradipine—Mental disorder—Doxorubicin—testicular cancer	0.000998	0.00114	CcSEcCtD
Isradipine—Ill-defined disorder—Epirubicin—testicular cancer	0.000994	0.00114	CcSEcCtD
Isradipine—Vomiting—Etoposide—testicular cancer	0.000992	0.00114	CcSEcCtD
Isradipine—Malnutrition—Doxorubicin—testicular cancer	0.000992	0.00114	CcSEcCtD
Isradipine—Anaemia—Epirubicin—testicular cancer	0.000991	0.00114	CcSEcCtD
Isradipine—Rash—Etoposide—testicular cancer	0.000984	0.00113	CcSEcCtD
Isradipine—Dermatitis—Etoposide—testicular cancer	0.000983	0.00113	CcSEcCtD
Isradipine—Headache—Etoposide—testicular cancer	0.000978	0.00112	CcSEcCtD
Isradipine—Chest pain—Methotrexate—testicular cancer	0.000975	0.00112	CcSEcCtD
Isradipine—Arthralgia—Methotrexate—testicular cancer	0.000975	0.00112	CcSEcCtD
Isradipine—Tension—Doxorubicin—testicular cancer	0.000973	0.00112	CcSEcCtD
Isradipine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000968	0.00111	CcSEcCtD
Isradipine—Malaise—Epirubicin—testicular cancer	0.000966	0.00111	CcSEcCtD
Isradipine—Discomfort—Methotrexate—testicular cancer	0.000963	0.0011	CcSEcCtD
Isradipine—Nervousness—Doxorubicin—testicular cancer	0.000963	0.0011	CcSEcCtD
Isradipine—Syncope—Epirubicin—testicular cancer	0.000961	0.0011	CcSEcCtD
Isradipine—Leukopenia—Epirubicin—testicular cancer	0.000959	0.0011	CcSEcCtD
Isradipine—Back pain—Doxorubicin—testicular cancer	0.000959	0.0011	CcSEcCtD
Isradipine—Muscle spasms—Doxorubicin—testicular cancer	0.000953	0.00109	CcSEcCtD
Isradipine—Palpitations—Epirubicin—testicular cancer	0.000947	0.00109	CcSEcCtD
Isradipine—Loss of consciousness—Epirubicin—testicular cancer	0.000942	0.00108	CcSEcCtD
Isradipine—Cough—Epirubicin—testicular cancer	0.000935	0.00107	CcSEcCtD
Isradipine—Anaphylactic shock—Methotrexate—testicular cancer	0.000935	0.00107	CcSEcCtD
Isradipine—Vision blurred—Doxorubicin—testicular cancer	0.000935	0.00107	CcSEcCtD
Isradipine—Nausea—Etoposide—testicular cancer	0.000927	0.00106	CcSEcCtD
Isradipine—Ill-defined disorder—Doxorubicin—testicular cancer	0.00092	0.00105	CcSEcCtD
Isradipine—Nervous system disorder—Methotrexate—testicular cancer	0.000917	0.00105	CcSEcCtD
Isradipine—Anaemia—Doxorubicin—testicular cancer	0.000917	0.00105	CcSEcCtD
Isradipine—Thrombocytopenia—Methotrexate—testicular cancer	0.000915	0.00105	CcSEcCtD
Isradipine—Arthralgia—Epirubicin—testicular cancer	0.000912	0.00105	CcSEcCtD
Isradipine—Chest pain—Epirubicin—testicular cancer	0.000912	0.00105	CcSEcCtD
Isradipine—Anxiety—Epirubicin—testicular cancer	0.000909	0.00104	CcSEcCtD
Isradipine—Skin disorder—Methotrexate—testicular cancer	0.000908	0.00104	CcSEcCtD
Isradipine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000906	0.00104	CcSEcCtD
Isradipine—Hyperhidrosis—Methotrexate—testicular cancer	0.000904	0.00104	CcSEcCtD
Isradipine—Discomfort—Epirubicin—testicular cancer	0.000901	0.00103	CcSEcCtD
Isradipine—Malaise—Doxorubicin—testicular cancer	0.000894	0.00103	CcSEcCtD
Isradipine—Dry mouth—Epirubicin—testicular cancer	0.000892	0.00102	CcSEcCtD
Isradipine—Syncope—Doxorubicin—testicular cancer	0.000889	0.00102	CcSEcCtD
Isradipine—Leukopenia—Doxorubicin—testicular cancer	0.000888	0.00102	CcSEcCtD
Isradipine—Palpitations—Doxorubicin—testicular cancer	0.000876	0.001	CcSEcCtD
Isradipine—Anaphylactic shock—Epirubicin—testicular cancer	0.000875	0.001	CcSEcCtD
Isradipine—Oedema—Epirubicin—testicular cancer	0.000875	0.001	CcSEcCtD
Isradipine—Hypotension—Methotrexate—testicular cancer	0.000873	0.001	CcSEcCtD
Isradipine—Loss of consciousness—Doxorubicin—testicular cancer	0.000872	0.000999	CcSEcCtD
Isradipine—Cough—Doxorubicin—testicular cancer	0.000865	0.000992	CcSEcCtD
Isradipine—Shock—Epirubicin—testicular cancer	0.000861	0.000987	CcSEcCtD
Isradipine—Nervous system disorder—Epirubicin—testicular cancer	0.000858	0.000983	CcSEcCtD
Isradipine—Thrombocytopenia—Epirubicin—testicular cancer	0.000856	0.000982	CcSEcCtD
Isradipine—Tachycardia—Epirubicin—testicular cancer	0.000854	0.000979	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000852	0.000976	CcSEcCtD
Isradipine—Skin disorder—Epirubicin—testicular cancer	0.00085	0.000974	CcSEcCtD
Isradipine—Hyperhidrosis—Epirubicin—testicular cancer	0.000846	0.000969	CcSEcCtD
Isradipine—Insomnia—Methotrexate—testicular cancer	0.000845	0.000969	CcSEcCtD
Isradipine—Chest pain—Doxorubicin—testicular cancer	0.000844	0.000968	CcSEcCtD
Isradipine—Arthralgia—Doxorubicin—testicular cancer	0.000844	0.000968	CcSEcCtD
Isradipine—Anxiety—Doxorubicin—testicular cancer	0.000841	0.000965	CcSEcCtD
Isradipine—Paraesthesia—Methotrexate—testicular cancer	0.000839	0.000962	CcSEcCtD
Isradipine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000838	0.000961	CcSEcCtD
Isradipine—Discomfort—Doxorubicin—testicular cancer	0.000834	0.000956	CcSEcCtD
Isradipine—Dyspnoea—Methotrexate—testicular cancer	0.000833	0.000955	CcSEcCtD
Isradipine—Somnolence—Methotrexate—testicular cancer	0.000831	0.000953	CcSEcCtD
Isradipine—Dry mouth—Doxorubicin—testicular cancer	0.000826	0.000947	CcSEcCtD
Isradipine—Dyspepsia—Methotrexate—testicular cancer	0.000823	0.000943	CcSEcCtD
Isradipine—Hypotension—Epirubicin—testicular cancer	0.000817	0.000937	CcSEcCtD
Isradipine—Decreased appetite—Methotrexate—testicular cancer	0.000812	0.000931	CcSEcCtD
Isradipine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000809	0.000928	CcSEcCtD
Isradipine—Oedema—Doxorubicin—testicular cancer	0.000809	0.000928	CcSEcCtD
Isradipine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000807	0.000925	CcSEcCtD
Isradipine—Fatigue—Methotrexate—testicular cancer	0.000806	0.000924	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000797	0.000914	CcSEcCtD
Isradipine—Shock—Doxorubicin—testicular cancer	0.000796	0.000913	CcSEcCtD
Isradipine—Nervous system disorder—Doxorubicin—testicular cancer	0.000794	0.00091	CcSEcCtD
Isradipine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000792	0.000908	CcSEcCtD
Isradipine—Insomnia—Epirubicin—testicular cancer	0.000791	0.000907	CcSEcCtD
Isradipine—Tachycardia—Doxorubicin—testicular cancer	0.00079	0.000906	CcSEcCtD
Isradipine—Skin disorder—Doxorubicin—testicular cancer	0.000786	0.000901	CcSEcCtD
Isradipine—Paraesthesia—Epirubicin—testicular cancer	0.000785	0.0009	CcSEcCtD
Isradipine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000782	0.000897	CcSEcCtD
Isradipine—Dyspnoea—Epirubicin—testicular cancer	0.00078	0.000894	CcSEcCtD
Isradipine—Somnolence—Epirubicin—testicular cancer	0.000778	0.000891	CcSEcCtD
Isradipine—Feeling abnormal—Methotrexate—testicular cancer	0.00077	0.000883	CcSEcCtD
Isradipine—Dyspepsia—Epirubicin—testicular cancer	0.00077	0.000883	CcSEcCtD
Isradipine—Decreased appetite—Epirubicin—testicular cancer	0.00076	0.000872	CcSEcCtD
Isradipine—Hypotension—Doxorubicin—testicular cancer	0.000756	0.000867	CcSEcCtD
Isradipine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000755	0.000866	CcSEcCtD
Isradipine—Fatigue—Epirubicin—testicular cancer	0.000754	0.000865	CcSEcCtD
Isradipine—Constipation—Epirubicin—testicular cancer	0.000748	0.000858	CcSEcCtD
Isradipine—Urticaria—Methotrexate—testicular cancer	0.000742	0.000851	CcSEcCtD
Isradipine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000737	0.000845	CcSEcCtD
Isradipine—Insomnia—Doxorubicin—testicular cancer	0.000732	0.000839	CcSEcCtD
Isradipine—Paraesthesia—Doxorubicin—testicular cancer	0.000727	0.000833	CcSEcCtD
Isradipine—Dyspnoea—Doxorubicin—testicular cancer	0.000722	0.000827	CcSEcCtD
Isradipine—Feeling abnormal—Epirubicin—testicular cancer	0.000721	0.000826	CcSEcCtD
Isradipine—Somnolence—Doxorubicin—testicular cancer	0.000719	0.000825	CcSEcCtD
Isradipine—Dyspepsia—Doxorubicin—testicular cancer	0.000712	0.000817	CcSEcCtD
Isradipine—Decreased appetite—Doxorubicin—testicular cancer	0.000704	0.000807	CcSEcCtD
Isradipine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000699	0.000801	CcSEcCtD
Isradipine—Fatigue—Doxorubicin—testicular cancer	0.000698	0.0008	CcSEcCtD
Isradipine—Urticaria—Epirubicin—testicular cancer	0.000695	0.000797	CcSEcCtD
Isradipine—Constipation—Doxorubicin—testicular cancer	0.000692	0.000793	CcSEcCtD
Isradipine—Asthenia—Methotrexate—testicular cancer	0.000671	0.000769	CcSEcCtD
Isradipine—Feeling abnormal—Doxorubicin—testicular cancer	0.000667	0.000765	CcSEcCtD
Isradipine—Pruritus—Methotrexate—testicular cancer	0.000661	0.000758	CcSEcCtD
Isradipine—Urticaria—Doxorubicin—testicular cancer	0.000643	0.000737	CcSEcCtD
Isradipine—Diarrhoea—Methotrexate—testicular cancer	0.000639	0.000733	CcSEcCtD
Isradipine—Asthenia—Epirubicin—testicular cancer	0.000628	0.000719	CcSEcCtD
Isradipine—Pruritus—Epirubicin—testicular cancer	0.000619	0.000709	CcSEcCtD
Isradipine—Dizziness—Methotrexate—testicular cancer	0.000618	0.000709	CcSEcCtD
Isradipine—Diarrhoea—Epirubicin—testicular cancer	0.000598	0.000686	CcSEcCtD
Isradipine—Vomiting—Methotrexate—testicular cancer	0.000594	0.000681	CcSEcCtD
Isradipine—Rash—Methotrexate—testicular cancer	0.000589	0.000676	CcSEcCtD
Isradipine—Dermatitis—Methotrexate—testicular cancer	0.000589	0.000675	CcSEcCtD
Isradipine—Headache—Methotrexate—testicular cancer	0.000586	0.000671	CcSEcCtD
Isradipine—Asthenia—Doxorubicin—testicular cancer	0.000581	0.000666	CcSEcCtD
Isradipine—Dizziness—Epirubicin—testicular cancer	0.000578	0.000663	CcSEcCtD
Isradipine—Pruritus—Doxorubicin—testicular cancer	0.000573	0.000656	CcSEcCtD
Isradipine—Vomiting—Epirubicin—testicular cancer	0.000556	0.000638	CcSEcCtD
Isradipine—Nausea—Methotrexate—testicular cancer	0.000555	0.000636	CcSEcCtD
Isradipine—Diarrhoea—Doxorubicin—testicular cancer	0.000554	0.000635	CcSEcCtD
Isradipine—Rash—Epirubicin—testicular cancer	0.000551	0.000632	CcSEcCtD
Isradipine—Dermatitis—Epirubicin—testicular cancer	0.000551	0.000632	CcSEcCtD
Isradipine—Headache—Epirubicin—testicular cancer	0.000548	0.000628	CcSEcCtD
Isradipine—Dizziness—Doxorubicin—testicular cancer	0.000535	0.000614	CcSEcCtD
Isradipine—Nausea—Epirubicin—testicular cancer	0.00052	0.000596	CcSEcCtD
Isradipine—Vomiting—Doxorubicin—testicular cancer	0.000515	0.00059	CcSEcCtD
Isradipine—Rash—Doxorubicin—testicular cancer	0.00051	0.000585	CcSEcCtD
Isradipine—Dermatitis—Doxorubicin—testicular cancer	0.00051	0.000584	CcSEcCtD
Isradipine—Headache—Doxorubicin—testicular cancer	0.000507	0.000581	CcSEcCtD
Isradipine—Nausea—Doxorubicin—testicular cancer	0.000481	0.000551	CcSEcCtD
